Western blot analysis showed that Fatostain treatment decreased the expression of HB‐associated genes like AFP, OCT4, GPC3, and DUSP9, indicating that SREBF2 inhibition could reduce hepatoblastoma stemness (Figure S16C, Supporting Information). This evidence concerns the gene POU5F1 and hepatoblastoma.